This is an amended filing
REYON PHARMACEUTICAL CO., LTD Convertible bond issue cut from KRW 10.0 billion to KRW 9.0 billion, conversion price KRW 10,170
RAI summary · Not investment advice
REYON PHARMACEUTICAL CO., LTD cut its 5th private convertible bond issue from KRW 10.0 billion to KRW 9.0 billion; at KRW 10,170 per share, full conversion would add 4.54% of total shares.
Total face value
KRW 9.0 billion
4.54% of total shares · 49.15% including outstanding bonds · changed from KRW 10.0 billion
Key facts
- Bond type
- Series 5 unsecured private convertible bonds
- Working capital
- KRW 9.0 billionCorporate operating expenses · changed from KRW 10.0 billion
- Coupon rate
- 0.0%
- Yield to maturity
- 3.0%115.9274% of face value repaid at maturity
- Maturity date
- Oct 28, 2031
- Conversion price per share
- KRW 10,170
- Convertible shares
- 884,955 sharesChanged from 983,284 shares
- % of total shares
- 4.54%Changed from 5.09%
- Conversion period
- Oct 28, 2027 – Sep 28, 2031
- Call option limit
- Up to KRW 1.8 billion (20% call option)The company or its designee · previously up to KRW 2.0 billion
- First put date
- Oct 28, 2028
- Subscriber
- A technology investment partnershipKRW 5.0 billion
- Subscriber
- An investment advisory firmKRW 2.8 billion · changed from KRW 3.8 billion
- Subscriber
- A securities firm (as trustee of a private fund)KRW 700.0 million
- Subscriber
- A technology investment partnershipKRW 500.0 million
- Payment date
- Oct 28, 2026
- Board resolution date
- Oct 8, 2026
Commentary
AI commentary · Not investment advice
What happened
REYON PHARMACEUTICAL cut the size of the convertible bond it approved earlier this month from KRW 10.0 billion to KRW 9.0 billion. A convertible bond is a bond that can later be turned into shares. The cut comes from an investment advisory firm, whose share fell from KRW 3.8 billion to KRW 2.8 billion. The other buyers are a technology investment partnership with KRW 5.0 billion, a fund trustee with KRW 700.0 million and another partnership with KRW 500.0 million. The conversion price stays at KRW 10,170.
In the company's terms
Up to 884,955 new shares could now be issued, or 4.54% of total shares. Including the unconverted 3rd and 4th series bonds, 9,134,723 shares could be issued, or 49.15% of shares already issued. All the money will go to corporate operating expenses.
What changes for shareholders
Conversion is possible from October 28, 2027 to September 28, 2031. The conversion price can be lowered if the share price falls, but not below KRW 8,136. The company or its designee can call back up to KRW 1.8 billion of the bonds (a call option). Holders can ask for early repayment from October 28, 2028 (a put option). The coupon is 0.0%, and holders at maturity get back 115.9274% of face value.
Earlier Material Event Report filings from this company
| Filed | Title | Key figure · Note |
|---|---|---|
| 26.11.022026.11.02 | Material Event Report | KRW 3.0 billion |
| 26.10.262026.10.26 | Material Event Report | KRW 950.0 million · 0.52% of total shares · handling to be decided later by the board |
Show Korean comments
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist